U.S. Markets open in 5 hrs 40 mins

Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks

Stock Research Monitor: EARS, NLNK, and OMER

LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want a free Stock Review on OHRP sign up now at www.wallstequities.com/registration. For today, WallStEquities.com observes Auris Medical Holding AG (EARS), NewLink Genetics Corp. (NLNK), OHR Pharmaceutical Inc. (OHRP), and Omeros Corp. (OMER). The Biotechnology industry consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Auris Medical Holding

Shares in Zug, Switzerland headquartered Auris Medical Holding AG plummeted 21.13%, ending Thursday’s trading session at $0.56. The stock recorded a trading volume of 1.00 million shares, which was higher than its three months average volume of 466,440 shares. The Company’s shares are trading 53.05% below their 50-day moving average. Moreover, shares of the Company, which focuses on the development of novel products for the treatment of inner ear disorders, have a Relative Strength Index (RSI) of 20.28.

On July 03rd, 2018, Auris Medical announced the publication of an article confirming dose-dependent effects of betahistine and their relationship to bioavailability in a cat model of surgery-induced acute vertigo. The peer-reviewed article, “Betahistine treatment in a cat model of vestibular pathology: pharmacokinetic and pharmacodynamic approaches,” was published in Frontiers in Neurology, the second most-cited open-access journal in clinical neurology. Get the full research report on EARS for free by clicking below at:

www.wallstequities.com/registration/?symbol=EARS

NewLink Genetics

Ames, Iowa headquartered NewLink Genetics Corp.’s stock rose slightly by 0.41%, closing the day at $4.87 with a total trading volume of 228,297 shares. The Company’s shares have advanced 8.22% in the previous three months. The stock is trading 4.76% below its 50-day moving average. Additionally, shares of NewLink Genetics, which focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer, have an RSI of 43.92.

On July 10th, 2018, NewLink Genetics announced that it will release its Q2 2018 financial results on July 31st, 2018. The Company has scheduled a conference call for 4:30 p.m. ET that same day to discuss these results and give an update on its clinical development, corporate strategy, and cash guidance. The conference call will be webcast live, and a link can be accessed on the Company’s website. Access the free research report on NLNK now by signing up at:

www.wallstequities.com/registration/?symbol=NLNK

OHR Pharmaceutical

On Thursday, shares in New York headquartered OHR Pharmaceutical Inc. recorded a trading volume of 140,494 shares. The stock ended the day 3.26% lower at $0.21. The Company’s shares are trading below their 50-day moving average by 0.90%. Furthermore, shares of OHR Pharmaceutical, which focuses on the development of novel therapies for the treatment of ophthalmic diseases, have an RSI of 49.76. Are you already registered with Wall St. Equities? Do so now for free, and get the report on OHRP at:

www.wallstequities.com/registration/?symbol=OHRP

Omeros

Seattle, Washington-based Omeros Corp.’s stock jumped 4.63%, finishing yesterday’s session at $21.00 with a total trading volume of 911,334 shares. The Company’s shares have advanced 10.76% in the last month, 39.81% in the previous three months, and 5.58% over the past year. The stock is trading above its 50-day and 200-day moving averages by 10.41% and 23.98%, respectively. Additionally, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 60.40.

On June 27th, 2018, Omeros announced that it has obtained regulatory authority and ethics committee clearance to start the Phase-1 clinical trial evaluating its lead phosphodiesterase 7 inhibitor from the Company’s OMS527 program. First subject dosing is expected this month. Following Phase 1 completion, the Company plans to conduct its initial OMS527 Phase-2 clinical trial in patients with nicotine addiction.

On July 12th, 2018, research firm Seaport Global Securities initiated a 'Buy' rating on the Company's stock, with a target price of $30 per share. Aspiring Member, please take a moment to register below for your free research report on OMER at:

www.wallstequities.com/registration/?symbol=OMER

Wall St.Equities:

Wall St. Equities (WSE) producesregular sponsored and non-sponsored reports, articles, stock market blogs, andpopular investment newsletters covering equities listed on NYSE and NASDAQ andmicro-cap stocks. WSE has two distinct and independent departments. Onedepartment produces non-sponsored analyst certified content generally in theform of press releases, articles and reports covering equities listed on NYSEand NASDAQ and the other produces sponsored content (in most cases not reviewedby a registered analyst), which typically consists of compensated investmentnewsletters, articles and reports covering listed stocks and micro-caps. Suchsponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directlyor indirectly; for producing or publishing this document.

PRESS RELEASEPROCEDURES:

The non-sponsored content containedherein has been prepared by a writer (the "Author") and is factchecked and reviewed by a third-party research service company (the"Reviewer") represented by a credentialed financial analyst [forfurther information on analyst credentials, please email info@wallstequities.com.Rohit Tuli, a CFA® charterholder (the "Sponsor"), providesnecessary guidance in preparing the document templates. The Reviewer hasreviewed and revised the content, as necessary, based on publicly availableinformation which is believed to be reliable. Content is researched, writtenand reviewed on a reasonable-effort basis. The Reviewer has not performed anyindependent investigations or forensic audits to validate the informationherein. The Reviewer has only independently reviewed the information providedby the Author according to the procedures outlined by WSE. WSE is not entitledto veto or interfere in the application of such procedures by the third-partyresearch service company to the articles, documents or reports, as the case maybe. Unless otherwise noted, any content outside of this document has noassociation with the Author or the Reviewer in any way.

NOWARRANTY

WSE, the Author, and the Reviewer arenot responsible for any error which may be occasioned at the time of printingof this document or any error, mistake or shortcoming. No liability is acceptedwhatsoever for any direct, indirect or consequential loss arising from the useof this document. WSE, the Author, and the Reviewer expressly disclaim anyfiduciary responsibility or liability for any consequences, financial orotherwise arising from any reliance placed on the information in this document.Additionally, WSE, the Author, and the Reviewer do not (1) guarantee theaccuracy, timeliness, completeness or correct sequencing of the information, or(2) warrant any results from use of the information. The included informationis subject to change without notice.

NOT ANOFFERING

This document is not intended as anoffering, recommendation, or a solicitation of an offer to buy or sell thesecurities mentioned or discussed, and is to be used for informational purposesonly. Please read all associated disclosures and disclaimers in full beforeinvesting. Neither WSE nor any party affiliated with us is a registeredinvestment adviser or broker-dealer with any agency or in any jurisdictionwhatsoever. To download our report(s), read our disclosures, or for moreinformation, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, orcomments reach out to us directly. If you're a company,we are covering and wish to no longer feature on our coverage list contact usvia email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Fridayat:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, ShawCenter Singapore 228

CFA® and Chartered FinancialAnalyst® are registered trademarks owned by CFA Institute.

SOURCE:Wall St. Equities